-

Glooko to Expand EMEA CGM Connectivity with Roche Accu-Chek® SmartGuide Integration

First diabetes data management platform outside of Roche’s ecosystem to integrate with Accu-Chek SmartGuide CGM, bringing more choice and a more complete view of data to people with diabetes and their care teams.

Development is complete and Integrations will be available in key European markets over the coming weeks

GOTHENBURG, Sweden--(BUSINESS WIRE)--Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing challenges of glycemic safety and diabetes management across care settings, today announced that the Glooko platform will integrate with the Roche Accu-Chek SmartGuide continuous glucose monitoring (CGM) solution across select European countries, subject to local availability.*

By integrating Roche’s Accu-Chek SmartGuide CGM into the Glooko platform, we’re expanding choice for people with diabetes and clinicians.

Share

This integration will enable people using the Accu-Chek SmartGuide CGM to bring their CGM data into Glooko, alongside data from other connected diabetes and health monitoring devices. This can reduce the administrative burden for healthcare teams, allow for the viewing of key insights in one place, and support effective collaboration between patient visits.

Accu-Chek SmartGuide is Roche’s AI-enabled CGM solution designed to provide real-time glucose readings and predictive insights across multiple timeframes. The system includes the Accu-Chek SmartGuide sensor and an application to view and analyse CGM glucose values and predictions. With an all-in-one applicator and 14-day wear time, Accu-Chek SmartGuide is designed for people living with diabetes, 18 years of age and older. Built-in predictive capabilities help users anticipate glucose trends, including forecasts up to two hours ahead and overnight risk insights, supporting proactive diabetes management.

“Diabetes data is only powerful when it’s accessible, connected, and easy to act on,” said Mike Alvarez, Chief Executive Officer of Glooko. “By integrating Roche’s Accu-Chek SmartGuide CGM into the Glooko platform, we’re expanding choice for people with diabetes and clinicians. Now, they can bring Accu-Chek SmartGuide CGM data together with the rest of the patient’s health and medication therapy context, in a single experience designed to support better, more informed decisions.”

Glooko is the first diabetes data management platform outside of Roche’s ecosystem that will integrate with the Accu-Chek SmartGuide CGM. The integration is designed to help address a common challenge in diabetes care: data that lives in separate device-specific apps and portals, making it harder for patients and clinicians to see the full picture.

The Accu-Chek SmartGuide CGM integration will be available on the Glooko platform in key markets across Europe over the coming weeks, subject to country availability and local regulatory and market requirements. Healthcare organizations can contact their Glooko representative for details.

About Glooko

Glooko, Inc. is a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum. Glooko is uniquely positioned to be the enterprise partner of choice for healthcare providers seeking to reduce glycemic risk, improve safety, and support overburdened clinical teams with coordinated expertise across both outpatient and inpatient care settings. Learn more at www.glooko.com.

*Functionality will be rolled out on a market-by-market basis in Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Italy, the Netherlands, Norway, Sweden, and the United Kingdom.

Contacts

Media contacts
Glooko:
Julia Fuller
VP of Communications
press@glooko.com

Glooko, Inc.


Release Versions

Contacts

Media contacts
Glooko:
Julia Fuller
VP of Communications
press@glooko.com

Social Media Profiles
More News From Glooko, Inc.

Glooko Introduces the First and Only Pump Settings EHR Integration to Bring Insulin Pump Data Directly Into Clinical Workflows

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced the launch of its Insulin Pump Settings Electronic Health Record (EHR) Integration, a new and first-of-its-kind capability in its latest software release that visualizes critical insulin pump configuration data directly into the clinical workflow. For clinics caring for...

Glooko Announces FDA 510(k) Clearance for EndoTool IV Cloud

PALO ALTO, Calif.--(BUSINESS WIRE)--Glooko, Inc., a global digital health company focused on helping clinicians address the growing challenges of glycemic safety and diabetes management across the care continuum, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for EndoTool IV Cloud, the first FDA-cleared, cloud-based patient-specific insulin dosing platform. EndoTool IV Cloud is the cloud-based version of EndoTool IV, Glooko’s clinical decision supp...

Glooko and mylife Diabetes Care Expand Diabetes Data Management Partnership

GOTHENBURG, Sweden & BURGDORF, Switzerland--(BUSINESS WIRE)--Glooko, Inc. and mylife Diabetes Care today announced an agreement to further expand their partnership, under which Glooko will serve as mylife Diabetes Care’s primary data management platform for mylife products. This next step builds on the strong, well-established collaboration between the two companies, ensuring continuity in the way healthcare professionals and patients access data from mylife products, including mylife Loop, an...
Back to Newsroom